<DOC>
	<DOCNO>NCT00553267</DOCNO>
	<brief_summary>The primary objective trial demonstrate fix dose combination telmisartan 40mg + amlodipine 10mg ( T40/A10 ) fix dose combination telmisartan 80mg + amlodipine 10mg ( T80/A10 ) superior reduce blood pressure eight week compare amlodipine 10mg monotherapy ( A10 ) patient fail respond six week treatment A10 .</brief_summary>
	<brief_title>Telmisartan/Amlodipine ( 80/10 ) vs. Telmisartan/Amlodipine ( 40/10 ) vs. amlodipine10 Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>diagnosis essential hypertension blood pressure adequately control informed consent ( inadequate control define seat diastolic blood pressure ( DBP ) &gt; = 95 mmHg exist antihypertensive treatment seat DBP &gt; = 100 mmHg treatmentnaïve ) . failure respond six week treatment amlodipine 10mg . ( Failure respond define seat DBP &gt; = 90 mmHg . ) able stop current antihypertensive therapy without unacceptable risk patient . willing able provide write informed consent . pregnancy , breastfeeding , unwilling use effective contraception ( female childbearing potential ) . know suspected secondary hypertension . mean seat systolic blood pressure ( SBP ) &gt; =200 mmHg and/or mean seat DBP &gt; = 120 mmHg runin treatment mean seat SBP &gt; = 180 mmHg and/or mean seat DBP &gt; = 120 mmHg randomisation visit time randomise treatment . clinically significant hepatic impairment severe renal impairment bilateral renal artery stenosis renal artery stenosis solitary kidney post postrenal transplant . clinically relevant hyperkalaemia . uncorrected volume sodium depletion . primary aldosteronism . hereditary fructose lactose intolerance . symptomatic congestive heart failure . patient previously experience symptom characteristic angioedema treatment ACE inhibitor ARBs . history drug alcohol dependency within six month prior sign consent . concurrent participation another clinical trial investigational therapy within thirty day prior sign consent . hypertrophic obstructive cardiomyopathy , hemodynamically relevant stenosis aortic mitral valve . know allergic hypersensitivity component formulation investigation . ( Includes know hypersensitivity telmisartan ARBs amlodipine dihydropyridine CCBs . ) noncompliance study medication ( define less 80 % 120 % ) openlabel runin treatment period . current treatment antihypertensive agent , whether prescribed indication , safely stop ( investigator¿s decision ) start runin period . chronic administration medication know affect blood pressure , trial medication . clinical condition , opinion investigator , would allow safe completion protocol safe administration telmisartan amlodipine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>